ArticleIndian journal of endocrinology and metabolism
Serial Changes in Thyroid Hormones with Oral or Intravenous Bisphosphonates.
Article in Indian journal of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bisphosphonates (BP) used in osteoporosis management can induce an acute phase response, their short-term endocrine effects remain unclear. This study hypothesized that initial BP exposure elicits a non-thyroidal illness syndrome (NTIS)-like pattern and that thyroid autoimmunity may amplify this response. Methods: In this prospective cohort at a tertiary centre, 336 adults (93% postmenopausal women) were enrolled: 168 received first-dose BP therapy (zoledronic acid (ZA) =129; oral alendronate (ALN) = 39) and 168 matched controls (calcium/vitamin D). FT3, FT4, TSH, and erythrocyte sedimentation rate (ESR) were measured at baseline and on days 1, 2, 3, 7, and 42 with baseline anti-TPO Ab. Linear mixed-effects models with random intercepts evaluated group × time interactions, adjusting for age, sex, and body mass index. Results: BP recipients demonstrated a clear temporal pattern, FT3 declined significantly, reaching a nadir on Day 2 (mean difference -0.47 pg/mL vs controls, Conclusion: First-dose BP therapy, particularly ZA, induces a short-lived, reversible NTIS-like response amplified by thyroid autoimmunity. Early post-infusion thyroid testing may mimic hypothyroidism, re-evaluation after six to eight weeks is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.